Stock Financial Ratios

ONS / Oncobiologics, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)31.77
Enterprise Value ($M)31.80
Book Value ($M)-33.65
Book Value / Share-1.32
Price / Book-1.20
NCAV ($M)-47.71
NCAV / Share-1.87
Price / NCAV-1.20
Income Statement (mra) ($M)
Net Income-38.85
Balance Sheet (mrq) ($M)
Cash & Equivalents0.00
Cash / Share0.00
Quick Ratio0.14
Current Ratio0.14
Management Effectiveness (mra)
Return on Invested Capital (ROIC)1.16
Return on Assets (ROA)-1.64
Return on Equity (ROE)7.47
Identifiers and Descriptors
Central Index Key (CIK)1649989
Industry Groups
Share Statistics
Weighted Average Number Of Shares Outstanding Basic24,022,371
Weighted Average Number Of Diluted Shares Outstanding24,041,789
Preferred Stock Shares Outstanding0
Common Stock Shares Outstanding24,933,944
Common Shares Outstanding25,530,727
Weighted Average Number Diluted Shares Outstanding Adjustment24,041,789
Scoring Models
Piotroski F-Score0.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Property Plant And Equipment Gross Per Share0.00
Accounts Receivable Per Share0.00
Property Plant And Equipment Per Share0.00
Inventory Raw Materials Per Share0.00
Liabilities Per Share0.00
Long Term Debt Per Share0.00
Treasury Stock Per Share0.00
Cash Per Share0.00
Accounts Payable Per Share0.00
Assets Non Current Per Share0.00
Inventory Per Share0.00
Retained Earnings Per Share0.00
Liabilities And Stock Equity Per Share0.00
Assets Other Non Current Per Share0.00
Intangibles Per Share0.00
Inventory Work In Progress Per Share0.00
Goodwill Per Share0.00
Property Plant And Equipment Net Per Share0.00
Additional Paid In Capital Per Share0.00
Liabilities Current Per Share0.00
Debt Per Share0.00
Assets Per Share0.00
Deferred Income Tax Liabilities Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Cash And Equivalents Per Share0.00
Assets Other Current Per Share0.00
Inventory Finished Goods Per Share0.00
Liabilities Other Non Current Per Share0.00
Preferred Stock Value Outstanding Per Share0.00
Accumulated Depreciation And Depletion Per Share0.00
Equity Per Share0.00
Assets Current Per Share0.00
Minority Interest Per Share0.00

Peers -

Related News Stories

Your Daily Pharma Scoop: Ablynx Takeover Bid, Celgene Acquires Impact Biomedicines, Axovant Flops Again

2018-01-09 seekingalpha
Today we will discuss the hostile takeover bid from Novo Nordisk (NVO) for clinical-stage Belgian biotech company Ablynx (OTCPK:ABLYF). (411-6)

Your Daily Pharma Scoop: Portola BLA Review Process Delayed, DelMar Soars, Alexion Gets Nod For Soliris In Japan

2017-12-28 seekingalpha
Today we will discuss the implications of the delay in the review of Portola’s (PTLA) AndexXa BLA. The news sent PTLA shares down more than 10% on Tuesday. (31-4)

Your Daily Pharma Scoop: AEterna Zentaris Gets FDA Nod, Valeant Finalizes Sprout Sale, Roche Gets EC Approval

2017-12-21 seekingalpha
Today we will focus on the much anticipated FDA decision on AEterna Zentaris’ (AEZS) Macrilen for diagnosis of adult growth hormone deficiency. (150-5)

How Roche Is Shoring Up Against The Biosimilar Wave

2017-10-02 seekingalpha
In oncology, no company stands to face more competition from the incoming wave of biosimilars that Roche. (105-2)

CUSIP: 68235M105